Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.81 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.81 |
| ▸ | PLK4 | O00444 | 2/20 | 0.81 |
| ▸ | AURKA | O14965 | 2/20 | 0.81 |
| ▸ | STK16 | O75716 | 2/20 | 0.81 |
| ▸ | RET | P07949 | 2/20 | 0.81 |
| ▸ | FLT3 | P36888 | 2/20 | 0.81 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.81 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.81 |
| ▸ | MST1R | Q04912 | 2/20 | 0.81 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.81 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.81 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.81 |
| ▸ | ADCK1 | Q86TW2 | 2/20 | 0.81 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.81 |
| ▸ | NEK9 | Q8TD19 | 2/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.81 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 0.81 |
| ▸ | LATS1 | O95835 | 1/20 | 0.81 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2627470 | 0.95 | SYK (0.75) | SYKPTK2PLK4AURKASTK16 | |
| SCHEMBL12799688 | 0.94 | SYK (0.72) | SYKPTK2PLK4AURKASTK16 | |
| SCHEMBL16682499 | 0.93 | SYK (0.80) | SYKPTK2PLK4AURKASTK16 | |
| SCHEMBL13451897 | 0.92 | SYK (0.84) | SYKPTK2PLK4AURKASTK16 | |
| SCHEMBL2627484 | 0.92 | SYK (0.84) | SYKPTK2PLK4AURKASTK16 | |
| SCHEMBL20006821 | 0.91 | SYK (0.82) | SYKPTK2PLK4AURKASTK16 | |
| SCHEMBL28489482 | 0.91 | SYK (0.84) | SYKPTK2PLK4AURKASTK16 | |
| SCHEMBL17425860 | 0.90 | SYK (0.83) | SYKPTK2PLK4AURKASTK16 | |
| SCHEMBL16858283 | 0.90 | SYK (0.82) | SYKPTK2PLK4AURKASTK16 | |
| Fostamatinib SCHEMBL1201371 | 0.90 | SYK (1.00) | SYKPTK2PLK4AURKASTK16 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013420-B1 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20220152065-A1 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-RE48898-E1 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210283152-A1 | METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS | MIDCAP FINANCIAL TRUST | 2021-09-16 | — | — | US | disclosed |
| WO-2021183790-A1 | METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-09-16 | — | — | WO | disclosed |
| US-20200270271-A1 | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| US-10577381-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190292197-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-10357505-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180153912-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20110319613-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-7989448-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7563892-B1 | Prodrugs of 2,4 pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563892-B1 | Prodrugs of 2,4 pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7538108-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538108-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20090124580-A1 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades | RIGEL PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-7449458-B2 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades; tyrosine kinase Syk kinase inhibitor; collagen-induced platelet activation inhibitor | RIGEL PHARMACEUTICALS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292197-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2055/4885PTK2 3230/4885PLK4 909/4885 |
| US-20210283152-A1 | METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS | REN, JAK1, JAK2 | SYK 59/4885PTK2 137/4885PLK4 1490/4885 |
| US-20200270271-A1 | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | DPYD, TYMP, DCTD | SYK 2055/4885PTK2 3230/4885PLK4 909/4885 |
| US-20180153912-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2198/4885PTK2 4081/4885PLK4 596/4885 |
| US-20220152065-A1 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME | TSLP, IL1B, IL6 | SYK 6/4885PTK2 1954/4885PLK4 4287/4885 |
| US-20110319613-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2055/4885PTK2 3230/4885PLK4 909/4885 |
| US-20090124580-A1 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades | FCGR3B, FCER2, FCGR1A | SYK 8/4885PTK2 1489/4885PLK4 1817/4885 |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | MKI67, RET, HRAS | SYK 3090/4885PTK2 17/4885PLK4 207/4885 |
| US-10577381-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | DPYD, TYMP, DCTD | SYK 2055/4885PTK2 3230/4885PLK4 909/4885 |
| US-10357505-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | DPYD, TYMP, DCTD | SYK 2198/4885PTK2 4081/4885PLK4 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.